A5088552578- Restless Legs Syndrome Research
- Parkinson's Disease Mechanisms and Treatments
- Sleep and Wakefulness Research
- Sleep and related disorders
- Obstructive Sleep Apnea Research
- Circadian rhythm and melatonin
- Dysphagia Assessment and Management
- Parkinson's Disease and Spinal Disorders
- Youth Substance Use and School Attendance
- Child Nutrition and Feeding Issues
- Neurological disorders and treatments
- Tryptophan and brain disorders
- Cardiovascular Syncope and Autonomic Disorders
- Migraine and Headache Studies
- Multiple Sclerosis Research Studies
- Biomedical and Chemical Research
- Attention Deficit Hyperactivity Disorder
- Health and Wellbeing Research
- Pain Management and Placebo Effect
- Mycobacterium research and diagnosis
- Ergonomics and Musculoskeletal Disorders
- Polyomavirus and related diseases
- Electron Spin Resonance Studies
- Transcranial Magnetic Stimulation Studies
- Ocular Surface and Contact Lens
Helios Hospital Schwerin
2013-2025
University of Rostock
2010-2023
Janssen (Belgium)
2023
Philipps University of Marburg
2004-2016
Mundipharma (Germany)
2016
Virginia Commonwealth University
2016
Boston University
2016
German Centre for Cardiovascular Research
2016
Siesta Group (Austria)
2012
MED Institute
2009
Primary treatment of obstructive sleep apnea can be accompanied by a persistence excessive sleepiness despite adherence. Furthermore, effectiveness is limited poor Currently available pharmacologic options for the in this population are limited.
Since the publication of first European Federation Neurological Societies (EFNS) guidelines in 2005 on management restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances field. Furthermore, RLS is now a part routine neurological practice Europe. New drugs become available, and further randomized controlled trials undertaken. These were undertaken by EFNS collaboration with Society Sleep Research Society.To provide an evidence-based update...
Restless legs syndrome (RLS) is a neurological disorder with lifetime prevalence of 3-10%. in European studies. However, the diagnosis RLS primary care remains low and mistreatment common. The current article reports on considerations management that were made during Legs Syndrome Study Group (EURLSSG)-sponsored task force consisting experts practioners. sought to develop better understanding barriers practice overcome these diagnostic treatment algorithms. identified by include presentation...
The orexin system is a key regulator of sleep and wakefulness. In multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, placebo on treatment nights 1-week intervals. end point was efficiency (SE) measured by polysomnography; secondary points were objective latency to persistent (LPS), wake after onset (WASO), safety,...
Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. In two phase III, 12-week studies in patients with insomnia disorder, daridorexant improved sleep and daytime functioning while maintaining favorable safety profile. The objective this 40-week extension study was to assess long-term tolerability daridorexant. Adults disorder who completed were invited enroll double-blind study. Patients originally randomised (10 mg/25 mg/50 mg) remained on their respective...
JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1β/IL-18 release. In healthy volunteers, suppressed peripheral interleukin (IL)-1β release, and attenuated dexamphetamine-induced improvements of mood (visuo)motor performance in human dexamphetamine-challenge paradigm. depression, P2X7R inhibition may dampen immune-related dysregulation mood. These results suggest the impact most prominent situations where regulation disrupted. Total sleep...
Abstract We report the first large‐scale double‐blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated fixed daily doses of 2 or 3 mg CAB 200 300 levodopa 30 weeks. Efficacy was assessed by changes in IRLS (International Severity Scale) time discontinuation treatment due loss efficacy augmentation. 361 418 screened patients...
The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month was conducted in six countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa flexibly up-titrated to a maximum dose of 600 mg/day. Presence diagnosed independently by two international experts using established criteria. In addition severity rating scale...
Summary In 2010 the European Medicines Agency withdrew indication of modafinil for treatment obstructive sleep apnea, shift work disorder and idiopathic hypersomnia ( IH ). uncontrolled studies, has been reported to be efficacious in disorders. We therefore performed a randomized, placebo‐controlled study with aim proving efficacy these patients. Drug‐free patients without long according ICSD 2 criteria, age >18 years disease duration >2 were included. After washout phase, at baseline...
Objective:To investigate the efficacy and safety of levodopa plus benserazide in treatment restless legs syndrome (RLS), terms frequency periodic limb movements (PLMs), objective subjective criteria sleep, onset action, withdrawal effects.
<b><i>Objective:</i></b> To assess the efficacy and safety of dopamine agonist cabergoline (CAB) in patients with restless legs syndrome (RLS). <b><i>Methods:</i></b> Patients moderate to severe RLS were randomized into four groups receiving placebo, 0.5 mg, 1 or 2 mg CAB once daily a double-blind, placebo-controlled, multicenter dose-finding trial followed by an open long-term extension 47 weeks. Efficacy was assessed RLS-6 scales International Study Group severity scale (IRLS)....
Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies patient experiences solriamfetol. We report data patients OSA EDS Germany (N = 83). was a retrospective chart review conducted among physicians Germany. Eligible were age ≥ 18 years who reached stable solriamfetol dose completed 6 weeks of treatment....
Summary This double‐blind, placebo‐controlled, two‐way crossover trial evaluated the efficacy and safety of daridorexant in patients with chronic insomnia comorbid nocturia. In total, 60 aged ≥55 years complaints for ≥3 months, Insomnia Severity Index (ISI) ≥13 voids/night ≥1 month were randomised (1:1) to 50 mg/placebo 4 weeks followed by after a 14–21‐day washout period. The primary endpoint was change from baseline Week (W) self‐reported total sleep time (sTST). Other endpoints included...